+

WO2008002929A3 - Sensibilisation croisée hétérologue destinée à améliorer l'activité agoniste - Google Patents

Sensibilisation croisée hétérologue destinée à améliorer l'activité agoniste Download PDF

Info

Publication number
WO2008002929A3
WO2008002929A3 PCT/US2007/072147 US2007072147W WO2008002929A3 WO 2008002929 A3 WO2008002929 A3 WO 2008002929A3 US 2007072147 W US2007072147 W US 2007072147W WO 2008002929 A3 WO2008002929 A3 WO 2008002929A3
Authority
WO
WIPO (PCT)
Prior art keywords
sensitization
agonist activity
heterologous cross
improved agonist
heterologous
Prior art date
Application number
PCT/US2007/072147
Other languages
English (en)
Other versions
WO2008002929A2 (fr
Inventor
Richard A Bond
Original Assignee
Inverseon Inc
Richard A Bond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inverseon Inc, Richard A Bond filed Critical Inverseon Inc
Publication of WO2008002929A2 publication Critical patent/WO2008002929A2/fr
Publication of WO2008002929A3 publication Critical patent/WO2008002929A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des procédés permettant d'améliorer l'efficacité d'agonistes de la prostacycline grâce à une sensibilisation hétérologue obtenue par une administration conjointe d'agonistes inverses bêta adrénergiques lors du traitement d'une hypertension pulmonaire et d'autres maladies soignées par un traitement chronique à base de prostacycline.
PCT/US2007/072147 2006-06-26 2007-06-26 Sensibilisation croisée hétérologue destinée à améliorer l'activité agoniste WO2008002929A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81668706P 2006-06-26 2006-06-26
US60/816,687 2006-06-26

Publications (2)

Publication Number Publication Date
WO2008002929A2 WO2008002929A2 (fr) 2008-01-03
WO2008002929A3 true WO2008002929A3 (fr) 2008-07-10

Family

ID=38846479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072147 WO2008002929A2 (fr) 2006-06-26 2007-06-26 Sensibilisation croisée hétérologue destinée à améliorer l'activité agoniste

Country Status (1)

Country Link
WO (1) WO2008002929A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10246403B2 (en) 2015-06-17 2019-04-02 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20060104913A1 (en) * 2003-06-27 2006-05-18 Merck Patent Gmbh Inhalable formulations for treating pulmonary hypertension and methods of using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060104913A1 (en) * 2003-06-27 2006-05-18 Merck Patent Gmbh Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIGGIN ET AL.: "Investigation of the Mechanism of G Protein: Effector Coupling by the Human and Mouse Prostacyclin Receptors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, 2002, pages 27053 - 27064 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10053414B2 (en) 2015-06-17 2018-08-21 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10246403B2 (en) 2015-06-17 2019-04-02 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Also Published As

Publication number Publication date
WO2008002929A2 (fr) 2008-01-03

Similar Documents

Publication Publication Date Title
WO2009129433A3 (fr) Agonistes des récepteurs alpha-adrénergiques destinés au traitement de la discopathie dégénérative
WO2008097277A3 (fr) Expression tcl1 dans la leucémie lymphocytaire chronique (llc) régulée par mir-29 et mir-181
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
MA28739B1 (fr) Derives de n-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dymethylpropyl) benzamide et composes associes comme inhibiteurs de la proteine kinesine fuseau (ksp) pour le traitement du cancer
WO2005082343A3 (fr) Activité enzymatique d'inhibiteurs d'amine oxidase à base d'amine et d'amide sensible aux semicarbazides (ssao), et adhésion induite par vap-1 utile pour le traitement de maladies
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2006138418A3 (fr) Amelioration de la performance cognitive avec des activateurs de sirtuine
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
WO2007149427A3 (fr) Inhibiteurs de tyrosine kinase
WO2006105527A3 (fr) Amyline et agonistes d'amyline utiles dans le traitement des maladies et troubles psychiatriques
WO2006119467A3 (fr) Modification d'activite de proteine
MY149630A (en) Antibodies against amyloid-beta peptide
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
EP2425849A3 (fr) Compositions et procédés d'utilisation d'anticorps anti-CS1 pour traiter plusieurs myélomes
TW200733974A (en) Materials and methods for treating chronic fibrotic disease
IL186491A0 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
WO2006122123A3 (fr) Procedes de soulagement de troubles et de leurs douleurs associees
AP2492A (en) Novel compositions of fungal inocula, method for the preparation thereof and use thereof for improving the growth of cultures
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
MY159244A (en) Method of reducing intraocular pressure in humans
WO2006078598A3 (fr) Inhibiteurs de la kinesine mitotique
WO2009114729A3 (fr) Composés, compositions et procédés de traitement des maladies et des troubles liés au stockage lysosomal
WO2008002929A3 (fr) Sensibilisation croisée hétérologue destinée à améliorer l'activité agoniste
WO2006101761A3 (fr) Inhibiteurs de kinesine mitotique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799046

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07799046

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载